Now live: Pro — the full 13F research suite for serious investorsSee pricing →
M28 Capital Management LP

Q3 2023 · 13F-HR

M28 Capital Management LPholdings as filed

Filed 2023-11-13 · accession 0000902664-23-005476

$87.2M
Reported value
11
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
Y95308105WVEWAVE LIFE SCIENCES LTD$40.5M46.4%7,044,500CommonSOLE
00534A102IVVDINVIVYD INC$15.7M18.0%9,248,250CommonSOLE
77313F106RCKTROCKET PHARMACEUTICALS INC$10.7M12.3%523,280CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$4.6M5.24%197,700CommonSOLE
82686Q101SLNSILENCE THERAPEUTICS PLC$3.6M4.10%363,800CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$3.2M3.67%121,200CommonSOLE
231269309CRISCURIS INC$2.8M3.19%421,951CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$2.5M2.85%1,910,600CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$1.8M2.08%67,400CommonSOLE
88322Q108TGTXTG THERAPEUTICS INC$1.8M2.08%216,600CommonSOLE
65344D109NEXIMMUNE INC$28,0090.03%133,442CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.